Under EPO's Shadow: Peres Jepchirchir's Suspension and the Lesson for Indian Athletics

30 August 2026, Sydney Marathon. Peres Jepchirchir ran 2:18:31. She beat compatriot Irene Chepet Cheptai by more than three minutes. It was her seventh World Marathon Major title, and Sydney had become the seventh major in 2026. But on the same day, in Kenya, an out-of-competition sample was taken from her. That sample tested positive for EPO. The Athletics Integrity Unit (AIU) has provisionally suspended her. In my ledger, that day's entry now splits into two: a performance, and a test. Reading them together is the real story.

I was at my desk in Hyderabad, watching the live stream. My ledger, running since 2026, was open in front of me — the year I typed 1,860 performances into a Lotus 1-2-3 file during the National Games in Hyderabad. Every number needs a witness. Jepchirchir's 2:18:31 is a number. But who is its witness? The clock in Sydney, or the sample taken in Kenya that tested positive for EPO?

Jepchirchir is 33. She won the 2026 Tokyo Olympic women's marathon and returned to Tokyo to win the World Championships in September 2026. She broke the women's half-marathon world record in 2026 and improved it three times in 2026. Her other major wins: New York Marathon 2026, Boston Marathon 2026, London Marathon 2026. In London 2026 she ran 2:16:16, a women's-only world record. Her Sydney victory added another line to her marathon legacy. But the AIU notice has put that legacy under a question mark.

EPO, or erythropoietin, is a natural substance produced in the kidneys that stimulates the creation of new red blood cells. When injected, it is detectable in urine or blood only for a short window. It increases the number of red blood cells, which carry oxygen to the muscles. That boosts endurance. In an event like the marathon, it can artificially enhance performance. The AIU rule is clear: a provisional suspension is a technical step, not a finding of guilt. But the gap between the record and the sample is where my reporting lives.

I have kept a ledger of every Indian performance since 2026. When six Indian women — including members of the 2026 Commonwealth and Asian Games 4x400 relay squads — received CAS-confirmed bans in 2026, I pulled three years of their splits. Their relay legs sat inside normal variance, but their individual 400m bests had collapsed by more than two seconds inside one season. Nobody asked why. I opened an anomaly file. It has never been closed. Jepchirchir's case is a new entry in that file, though a different country, a different event.

What does the data say? Jepchirchir's 2026 Sydney time of 2:18:31 is slower than her 2026 London time of 2:16:16. But Sydney's course is different. At the 2026 World Championships in Tokyo, she ran about 2:27:57 (heat and humidity). Sydney's 2:18:31 means she improved by nearly nine minutes in a year. That is not abnormal, but it is notable. In the marathon, a 5-10 minute swing based on weather, course and competition is common. But the EPO question is separate from the performance data. EPO's effect is to increase red blood cells, raising oxygen-carrying capacity. That can be decisive in the last 10km of a marathon.

My ledger records Jepchirchir's progression: - 2026 Tokyo Olympics: 2:27:20 - 2026 New York: 2:22:39 - 2026 Boston: 2:21:01 - 2026 London: 2:16:16 - 2026 World Championships Tokyo: 2:27:57 - 2026 Sydney: 2:18:31

This is a story of steady improvement, with fluctuations explained by course and weather. But the positive EPO sample brings this story into the realm of doubt. The question is not whether she took EPO — that is for the AIU process to decide. The question is: if EPO use is so common, why does our testing system fail to catch it? EPO is detectable only in a short window. Out-of-competition testing is the only way to catch it. Jepchirchir's sample was taken in Kenya, before the race. That is a step in the right direction.

But there is a twist. A single positive sample is not the whole story. In athletics, especially in Kenya, EPO cases have risen in recent years. In 2026, Athletics Kenya said it was taking strict action against doping. But system failures are not only the athlete's fault. In Kenya, athletics is an industry where young talents go to camps, foreign coaches arrive, and money is at stake. In India, we have our own 'quota economy' model — Railways, Services, police jobs, TOPS funding. This model gives athletes security, but also creates pressure. The six athletes of 2026 were a product of that pressure. Have we learned? In India, doping cases have not decreased in the last five years. National Anti-Doping Agency (NADA) data show more than 150 cases registered in 2026. That number is alarming.

Jepchirchir's case tells us that doping is not just India's or Kenya's problem; it is part of the global marathon economy. Sydney became the seventh World Marathon Major in 2026. That means there are now seven big marathons: Tokyo, Boston, London, Berlin, Chicago, New York and Sydney. Prize money, sponsorship and ranking points are huge. That increases the pressure on athletes. EPO looks like an easy path. But getting caught puts reputation and career on the line.

I have been on this beat since 2026. I have recorded Milkha Singh's fourth place in Rome 2026 and P.T. Usha's fourth in Los Angeles 2026 as measurements, not tragedies. 0.01 seconds is a measurement, not a metaphor. Similarly, Jepchirchir's 2:18:31 is a measurement. The positive EPO sample is another measurement. Putting them together is journalism.

My pre-registered forecast: By 2027, the AIU will increase out-of-competition testing in East Africa by 30%. In India, NADA and AFI should jointly launch a biological passport programme for marathon and long-distance athletes. If that does not happen, the next scandal will be at our door. Another entry will be added to the ledger, and we will ask again: where is the witness?

The AIU process will take months. The B-sample result will be crucial. If it is also positive, Jepchirchir could face a four-year ban, and her Sydney title will be questioned. Sydney's credibility as a World Major will also be affected. The lesson for India: we must increase testing in marathon and endurance events. Indian athletics pays little attention to long-distance running. We have the legacy of Milkha Singh and fourth places, but we lack depth in the marathon. Until we invest in the system, we cannot compete with powers like Kenya. And if we cannot stop doping, our achievements will also remain under a cloud.

The ledger said one thing. The season said another. I wrote down both.